88.7K
Downloads
199
Episodes
Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines. Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
Episodes
Friday Sep 08, 2023
The mission-driven biotech CEO
Friday Sep 08, 2023
Friday Sep 08, 2023
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Howard Berman, CEO and Chairman of the Board at Coya Therapeutics
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Howard, covering:
- How a neurology appointment with his father led to the creation of a biotech company focused on neurodegenerative, autoimmune, and metabolic diseases
- Having the DNA of an entrepreneur but taking the time to gain a big pharma foundation
- The harsh realities and characteristics required to start, fund, and grow a clinical-stage biotechnology company
- The need as a biotech CEO to be bullish, have confidence in your partners and be passionate about your disease... while celebrating the little successes
- Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel. He merged the company with Coya Therapeutics in 2021, where he currently serves as Chairman and CEO
He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines.
Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie. He spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for the development and initiation of collaborations, clinical trials and investigator-initiated trials.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.